因塞特 INCY 深 沪
等待开盘 10-07 09:30:00 美东时间
112.86
-1.270
-1.11%
华盛通- 最 高130.80
- 今 开114.13
- 成交量 118.12万股
- 最 低 111.67
- 昨 收 114.13
- 总市值 2505.49万
- 52周最高 132.60
- 市盈率 静 26.42
- 换手率 532.09%
- 52周最低 84.02
- 委 比 -88.46%
- 总股本 0.00亿
- 历史最高 153.15
- 量 比 0.80
- 振 幅 16.76%
- 历史最低 1.10
- 每 手 1
- 风险率 11.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment
The FDA approved Atebrioz by Mirum Pharmaceuticals and Incyte to treat FOP in patients aged 12 and older, reducing abnormal bone formation.
09-28 20:38
Incyte Says It's No Longer A One-Drug Story
Incyte (INCY) Q2 earnings beat estimates with $1.67B revenue, $3.09 EPS. Full-year sales guidance raised. Shares rally to new 52-week high.
07-29 03:10
This ConocoPhillips Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Top Wall Street analysts upgraded APA, INCY, COP, OVV, BWXT stocks with higher price targets. Check out what other analysts think before buying COP.
06-22 20:31
BMO Capital Upgrades Incyte to Market Perform, Raises Price Target to $94
BMO Capital analyst Evan Seigerman upgrades Incyte (NASDAQ:INCY) from Underperform to Market Perform and raises the price target from $75 to $94.
06-22 17:22
Incyte Strikes Agreement To Acquire Vega Therapeutics For $1.25B
Incyte (Nasdaq:INCY) announced today it has entered into a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC, for $1.25 billion. Star Therapeutics will be
06-08 19:20
A Glimpse Into The Expert Outlook On Incyte Through 13 Analysts
Throughout the last three months, 13 analysts have evaluated Incyte (NASDAQ:INC...
03-09 20:00
Incyte Sees FY26 Net Product Revenue Of $4.77B-$4.94B
2026 Financial GuidanceIncyte's guidance for the fiscal year 2026 is summarized below. Total net product revenue guidance of $4,770 to $4,940 million comprises: Jakafi net product revenue of $3,220 to $3,270 million and
02-10 20:03
Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth
Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.
01-12 18:47
Incyte Study Shows Lymphoma Drug Combo Slows Aggressive Blood Cancer
Incyte reported positive results from a trial of tafasitamab as a first-line treatment for adults with DLBCL. No new safety issues were seen.
01-06 00:59
Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms
Incyte Q3 revenue rose 20% to $1.37 billion, topping estimates, as Jakafi and Niktimvo fueled growth and the company raised its 2025 revenue outlook.
2025-10-29 02:44
